<DOC>
	<DOCNO>NCT01198054</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness post-induction lenalidomide patient de novo AML deletion 5q cytogenetic abnormality ( del ( 5q ) ) monosomy 5 ( -5 ) , obtain complete remission conventional induction chemotherapy . So , , obtain response treatment ( total resistance ) partial remission . At time , study evaluate security lenalidomide .</brief_summary>
	<brief_title>LENA-LMA-5 : Lenalidomide Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Confirm diagnosis AML accord WHO criteria ( Annex 4 ) . 2 . AML de novo ( ie , patient without documented history previous treatment antineoplastic agent radiotherapy oncological disease , hematological immunological , relate development secondary LMAs secondary AML patient without primary MDS del ( 5q ) 5 [ document history primary MDS transformation LMAs ] ) . 3 . Diagnostic confirmation abnormality del ( 5q ) 5 , without cytogenetic abnormality . It necessary del ( 5q ) include band 5q31 . 4 . Patients receive one cycle induction chemotherapy consist classical combination anthracycline cytarabine ( without etoposide third agent associate ) , regardless response . 5 . Patients evaluate response induction chemotherapy anthracyclines cytarabine ( without etoposide third agent partner ) classify accord criterion IWG.20 6 . ≤ 60 patient ineligible allogeneic hematopoietic progenitor . 7 . Patients &gt; 60 year eligible allogeneic hematopoietic stem cell , eligible HLAidentical brother . 8 . Accept use contraceptive method effective patient childbearing age reproductive potential ( see Section 6.5 pregnancy prevention plan ) . 9 . Ability understand voluntarily sign informed consent form . 10 . Age ≥ 18 year time signing informed consent form . 11 . Ability willingness follow schedule study visit . 1 . AML secondary treatment cytostatic immunosuppressive agent , myelodysplastic syndrome neoplastic disease . 2 . AML cytogenetic abnormality ( 15 , 17 ) , ( 8 ; 21 ) , ( 16 ; 16 ) inv ( 16 ) associate molecular rearrangement . 3 . Patients receive remission induction different regime cytarabine anthracycline / etoposide . 4 . ≤ 60 patient eligible allogeneic hematopoietic progenitor . 5 . Patients &gt; 60 year eligible allogeneic hematopoietic stem cell transplant HLAidentical brother . 6 . Patients evaluate response induction chemotherapy ( complete remission , partial remission resistance ( see Table 6 ) . 7 . ECOG 34 . 8 . Any following laboratory abnormality Serum creatinine &gt; 2.0 mg / dl ( 177 mmol / l ) . serum aspartate aminotransferase ( AST ) / glutamic oxalacetic transaminase serum ( SGOT ) alanine aminotransferase ( ALT ) / serum glutamate pyruvate transaminase ( SGPT ) &gt; 5.0 x upper limit normal ( ULN ) . total serum bilirubin &gt; 3 mg / dl . 9 . Patient known positive HIV serology . No HIV test require process selection . 10 . Any severe psychiatric condition disease prevent patient sign inform consent form patient involve unacceptable risk participate study . 11 . Any serious organic disease condition behave patient unacceptable risk participate study . 12 . Previous use cytotoxic chemotherapy agent experimental agent ( agent commercially available ) treatment AML . 13 . Pregnant breastfeeding ( see Section 6.5 pregnancy prevention plan ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>